Advertisement

Topics

GlaxoSmithKline initiates phase III study with mepolizumab in patients with nasal polyps

10:09 EDT 29 Jun 2017 | PharmaBiz

GlaxoSmithKline has announced the start of a phase III study with mepolizumab, an interleukin 5 (IL─5) antagonist, in patients with severe bilateral nasal polyps.

Original Article: GlaxoSmithKline initiates phase III study with mepolizumab in patients with nasal polyps

NEXT ARTICLE

More From BioPortfolio on "GlaxoSmithKline initiates phase III study with mepolizumab in patients with nasal polyps"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...